Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that management will present at two upcoming virtual investor conferences:
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at two upcoming virtual investor conferences:
- The Canaccord 41st Annual Growth Conference on Wednesday, August 11, 2021 at 11:00 a.m. (Eastern Time)
- The UBS Genomics 2.0 and MedTech Innovations Summit on Thursday, August 12, 2021 at 4:00 p.m. (Eastern Time)
To listen to the live audio webcast of the presentation, please visit investors.insulet.com. A replay of the audio webcast will also be available following the event.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005023/en/
Investor Relations:
Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com
Source: Insulet Corporation
View this news release online at:
http://www.businesswire.com/news/home/20210726005023/en
